Major Flaw Discovered in Widely Used Brain Mapping Technique

The findings, published in Nature Neuroscience in January 2026, reveal that lesion network mapping produces nearly identical results regardless of the condition being studied. The technique, developed in 2015, has been widely adopted to identify brain networks disrupted in conditions ranging from depression and addiction to Parkinson's disease and epilepsy.

The Discovery

Researchers led by Martijn van den Heuvel, professor of computational neuroscience at Vrije Universiteit Amsterdam, became suspicious when they noticed striking similarities between published lesion network mapping results for vastly different conditions. Networks identified for addiction, psychosis, post-traumatic stress disorder, migraine, epilepsy, and insomnia all showed activation of the same brain regions: the insular cortex, anterior cingulate cortex, and frontal cortex.

Van den Heuvel remarked that he could never find a logical link between conditions like psychosis and migraine, prompting a deeper investigation into the methodology.

The Research

The team re-analyzed 102 lesion network mapping networks across 72 studies and found that up to 74 percent of reported networks implicated the same brain regions. To test whether the method was actually identifying disease-specific circuits or simply reflecting properties of the reference data, researchers applied the technique to hypothetical lesions placed in random locations across the brain.

The results were revealing. The method produced essentially the same brain network map regardless of lesion location, demonstrating that the outputs reflect inherent properties of the reference connectivity data rather than biological information specific to particular disorders.

The fundamental flaw lies in how lesion network mapping repeatedly samples from a standard functional connectivity matrix. This repetitive sampling means that diverse brain changes, whether from actual patients, imaging data, or randomly generated locations, are consistently linked to the same general network patterns without providing disorder-specific information.

Clinical Implications

The discovery has serious implications for clinical applications. At least seven ongoing clinical trials are testing treatments based on brain targets identified through lesion network mapping. Some treatment approaches using transcranial magnetic stimulation and deep brain stimulation have been guided by these maps in attempts to alleviate neuropsychiatric symptoms.

Sophia Frangou, professor of psychiatry at the Icahn School of Medicine at Mount Sinai who was not involved in the study, commented that some treatments will be correct by accident, but most of the time, what researchers think is the optimal target really is not optimal.

Luca Cocchi, head of the Clinical Brain Networks Group at QIMR Berghofer Medical Research Institute and a study co-author, was blunt in his assessment. He stated that the method is probably not salvageable and that starting fresh with new analytical approaches will be best for the field.

Response from Developers

Aaron Boes, professor of pediatrics at the University of Iowa who co-developed lesion network mapping, acknowledged the study's findings while defending the method's potential utility. He noted that the results highlight an important cautionary point, that lesion network mapping can be prone to false-positive findings or nonspecific findings, and study designs need to be constructed carefully.

Michael Fox, professor of neurology at Harvard Medical School and co-developer of the technique, emphasized that the most important test of any brain mapping method is whether it can be used to help patients, which is not tested in this methods paper but is being tested in multiple clinical trials.

Looking Forward

Despite the concerning findings, there is some optimism about the future. Van den Heuvel expressed confidence that exposing these limitations would spur development of new network mapping methods grounded in fundamental principles. He described this potential progress as the silver lining of the discovery.

The revelation serves as a reminder of the importance of rigorous methodological validation in neuroscience research, particularly for techniques that inform clinical interventions. As the field moves forward, researchers will need to develop more robust approaches for mapping brain networks associated with specific neurological and psychiatric disorders.

The study highlights the need for careful scrutiny of widely adopted research methods and the value of independent replication and validation, even for established techniques. For the more than 200 studies that have used lesion network mapping, researchers may need to revisit their conclusions and consider alternative analytical approaches to verify their findings.